Sutro Biopharma, Inc.

STRO · Nasdaq · United States

Share price · STRO

$8.50-13.54 (-61.43%) 3M

close as of 2026-11-18 · 24h delayed · vol 307K (0.9x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when STRO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 13 Oct 2026-17.1%

    Nothing announced by STRO that day or the session before.

  2. 9 Oct 2026-6.9%
  3. 12 Aug 2026-14.9%
  4. 22 May 2026-16.5%
  5. 18 May 2026-11.5%
  6. 20 Apr 2026+9.6%
  7. 24 Mar 2026+10.5%
  8. 6 Mar 2026+12.4%
  9. 19 Feb 2026+12.2%
  10. 10 Feb 2026+11.9%

Share of unusual movement by asset

For each asset, the share of STRO's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
STRO-004
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—2%
Other company news (earnings, financing, releases naming no asset)—16%
Sessions with no dated event—82%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1
Tissue Factor (TF)Antibody–drug conjugate
Non-Small Cell Lung Cancer

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$9.1M$24M$47M+ $95M short-term inv.$31M-$22M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$9.8M$32M$54M+ $110M short-term inv.$39M-$38M operating cash flowreport ↗
2026-Q1$15M$37M$74M+ $129M short-term inv.$38M-$42M operating cash flowreport ↗
2025-Q3$9.7M$40M$66M+ $102M short-term inv.$57M-$38M operating cash flowreport ↗
2025-Q2$64M$38M$64M+ $141M short-term inv.$12M-$45M operating cash flowreport ↗
2025-Q1$17M$52M$106M+ $143M short-term inv.$76M-$68M operating cash flowreport ↗
2024-Q3$8.5M$62M$175M+ $214M short-term inv.$49M-$65M operating cash flowreport ↗
2024-Q2$26M$62M$91M+ $285M short-term inv.$48M$9.5M operating cash flowreport ↗
2024-Q1$13M$57M$65M+ $202M short-term inv.$58M-$65M operating cash flowreport ↗
2023-Q3$17M$46M$82M+ $239M short-term inv.$49M-$34M operating cash flowreport ↗
2023-Q2$10M$42M$235M+ $123M short-term inv.$39M-$31M operating cash flowreport ↗
2023-Q1$13M$39M$62M+ $189M short-term inv.$50M-$61M operating cash flowreport ↗
2022-Q3$25M$32M$97M+ $191M short-term inv.$19M$66M operating cash flowreport ↗
2022-Q2$28M$32M$79M+ $113M short-term inv.$26M-$3.2M operating cash flowreport ↗
2022-Q1$5.9M$30M$29M+ $143M short-term inv.$39M-$35M operating cash flowreport ↗
2021-Q3$8.5M$27M$31M+ $159M short-term inv.$31M-$24M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$102M$166M$58M+ $83M short-term inv.$48M-$177M operating cash flowreport ↗

For FY2025, Sutro Biopharma reported revenue of $102.48M, up 65.2% YoY from $62.04M, with R&D spend of $166.42M, down 34.0% YoY. Cash and equivalents were $58.13M, while total cash, cash equivalents and marketable securities were $141.4M as of December 31, 2025. Net loss was $191.09M.

Management guided that the recent $110.0M gross offering extends the cash runway into at least the second quarter of 2028. In the clinic, the Phase 1 trial of STRO-004 has completed dosing across three cohorts with initial data expected in mid-2026, STRO-006 is expected to enter clinical development in 2026, and STRO-227’s IND submission is targeted for 2026. Under the Astellas collaboration, the first dual-payload iADC program has entered the clinic and a second program entered IND-enabling toxicology, triggering milestone payments of $10M and $7.5M respectively.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$62M$252M$190M+ $127M short-term inv.$57M-$192M operating cash flowreport ↗
2023-FY$154M$180M$69M+ $264M short-term inv.$27M-$112M operating cash flowreport ↗
2022-FY$68M$137M$47M+ $255M short-term inv.$30M$3.5M operating cash flowreport ↗
2021-FY$62M$104M$30M+ $130M short-term inv.$26M-$82M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-18Gerber Hans-Peter · CHIEF SCIENTIFIC OFFICEROption exercise3,750——Form 4
2026-09-18Gerber Hans-Peter · CHIEF SCIENTIFIC OFFICERTax withholding1,345$15.34$21KForm 4
2026-09-18Gerber Hans-Peter · CHIEF SCIENTIFIC OFFICEROption exercise (derivative)3,750——Form 4
2026-06-05MATSUI CONNIE · directorAward / grant (derivative)10,000——Form 4
2026-06-05Dybbs Michael · directorAward / grant (derivative)10,000——Form 4
2026-06-05Hunter Heidi · directorAward / grant (derivative)10,000——Form 4
2026-06-05Jagpal Sukhi · directorAward / grant (derivative)10,000——Form 4
2026-06-05Lobacki Joseph M · directorAward / grant (derivative)10,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 71 reporting institutions held 14.1M shares ($342.7M, 85.2% of shares outstanding).

#InstitutionSharesValue
1BVF INC/IL1,251,788$31.2M
2Affinity Asset Advisors, LLC1,069,519$26.6M
3SAMSARA BIOCAPITAL, LLC1,062,872$26.5M
4Kynam Capital Management, LP872,558$21.7M
5ORBIMED ADVISORS LLC801,144$20.0M
6VANGUARD CAPITAL MANAGEMENT LLC720,442$17.9M
7PERCEPTIVE ADVISORS LLC715,307$17.8M
8RA CAPITAL MANAGEMENT, L.P.715,307$17.8M
9EVENTIDE ASSET MANAGEMENT, LLC715,307$17.8M
10Point72 Asset Management, L.P.692,111$17.2M
11ADAR1 Capital Management, LLC524,441$13.1M
12Velan Capital Investment Management LP512,160$12.8M
13Balyasny Asset Management L.P.465,792$11.6M
14Woodline Partners LP457,441$11.4M
15UBS Group AG392,871$9.8M